A rare ebolavirus species that, before 2026, had caused only two recognised outbreaks (Uganda 2007–2008, DRC 2012). The 2026 DRC + Uganda outbreak, declared a Public Health Emergency of International Concern by WHO on 17 May 2026, is the third recorded Bundibugyo outbreak. No vaccines or therapeutics approved for human use are known to be effective against Bundibugyo virus.
Last updated
What is Bundibugyo virus?
Bundibugyo virus (BDBV) is the ebolavirus species behind the May 2026 PHEIC. No approved vaccine or therapeutic targets it.
Bundibugyo ebolavirus was first identified in 2007 in Bundibugyo
District, western Uganda, where it caused 149 cases and 37 deaths
(CFR around 25%). A second outbreak followed in 2012 in DRC's
Orientale Province (57 cases, 29 deaths, CFR around 51%). The
third recognised outbreak began in early 2026 in Ituri Province,
DRC, with confirmed cross-border spread to Kampala, Uganda;
WHO declared a Public Health Emergency of International Concern
on 17 May 2026. None of the four FDA-approved Ebola products
(Ervebo, Zabdeno + Mvabea, Inmazeb, Ebanga) are licensed for
Bundibugyo virus; all target Zaire ebolavirus glycoprotein.
WHO declared a Public Health Emergency of International Concern on 17 May 2026. Third recognised Bundibugyo virus outbreak; no approved vaccines or therapeutics target this strain. Cross-border spread to Uganda confirmed via traveler-linked Kampala cases.
2012
DRC · Orientale Province
57
29
50.9%
Second recognised Bundibugyo virus outbreak. The 2026 outbreak shares geographic proximity (Ituri Province sits in the former Orientale Province area).
2007–2008
Uganda · Bundibugyo District
149
37
24.8%
First recognised Bundibugyo virus outbreak. The only one in the species record until the 2012 DRC and 2026 DRC + Uganda outbreaks.